SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius is trending as investors debate the impact of short-term volatility and distribution challenges against the company's long-term growth potential and market share expansion. The community is actively discussing potential acquisition rumors, the performance of the Alani Nu brand, and whether recent price fluctuations represent a generational buying opportunity or further downside risk.

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is trending following a significant surge in trading volume and share price, with the community actively discussing potential institutional accumulation and the stock's reclaim of the critical $5 price level. Investors remain focused on upcoming earnings and the company's long-term oncology pipeline, debating whether this momentum marks a sustained breakout or a temporary reaction to market activity.

REalloys, Inc. is engaged in the rebuilding of domestic supply chain resilience for rare earth elements and magnets. It is involved in recycling, mining, oxide production, metallization, alloying, and magnet manufacturing. The company was founded on October 4, 2011 and is headquartered in Boca Raton, FL.

REalloys Inc.

ALOY is trending as community members speculate on its role in the U.S. government's push for a domestic rare earth supply chain and its inclusion in the Russell 3000 index. Investors are actively debating the company's long-term potential as a critical military supplier versus concerns about volatility, dilution, and the speculative nature of its current financials.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is trending as the community closely monitors trial updates, including EMA approval for commercial GP2 peptide use and ongoing discussions regarding interim trial analysis protocols. Investors remain focused on the potential for institutional movement and strategic partnerships, as high short-interest dynamics continue to drive significant volatility in the stock.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group Inc is trending as investors debate the potential for a regulatory turnaround following the resignation of the FDA chief and speculation surrounding the company's prospects for a third BLA resubmission. The community is sharply divided, with some traders betting on a high-risk squeeze driven by institutional activity and political shifts, while others emphasize the firm's liquidity constraints, previous regulatory setbacks, and significant staffing reductions.

Bonk is a dog-themed memecoin on the Solana blockchain, launched on Christmas Day 2022 to revitalize the Solana community following the FTX collapse. Created by an anonymous team of 22 Solana developers and builders, Bonk distributed 50% of its total 100 trillion token supply via airdrop to community members including NFT collectors, developers, and artists.   The project positions itself as "the first Solana dog coin for the people, by the people," explicitly rejecting venture capital backing in favor of grassroots community ownership. What sets Bonk apart from other memecoins is its combination of fair launch mechanics, extensive ecosystem integration, and active deflationary strategy.   Built on Solana, BONK benefits from fast transaction speeds and low fees that make it practical for everyday use. Native products include LetsBonk.fun (a memecoin launchpad that briefly became Solana's market leader in 2025, surpassing Pump.fun with over 78% market share), BonkSwap (a decentralized exchange) and BonkBot (a Telegram trading bot with built-in burn mechanics).   BONK is available across 10 blockchain networks and listed on major exchanges including Binance, Coinbase, Kraken, and Robinhood. Governance is handled by BonkDAO, which holds 15% of the token supply and makes decisions through on-chain voting.   The community has organized several major burn events, most notably the December 2024 BURNmas campaign that destroyed 1.69 trillion tokens worth over $50 million. In September 2025, Nasdaq-listed Safety Shot, Inc. formed BONK Holdings LLC and acquired over 2.5% of the circulating supply (valued at $55-63 million), making BONK one of the first memecoins to attract formal corporate treasury adoption. Core contributor Nom was appointed to Safety Shot's board, and the company holds a 10% revenue share in LetsBonk.fun.  As with all memecoins, BONK is a highly speculative asset with substantial volatility. Its value is primarily driven by community sentiment, social media momentum, and meme culture rather than traditional utility.   The anonymous team, while common in the memecoin space, means investors should exercise appropriate caution. Despite these risks, Bonk has established itself as one of the most successful community-driven tokens in the Solana ecosystem, approaching 1 million unique holders and expanding from a simple memecoin into meaningful DeFi infrastructure.

BONK

BONK is experiencing significant volatility and community division following news of a large-scale treasury exploit, leading to intense debate over the token's long-term viability. Investors are sharply polarized, with some aggressively accumulating the dip while others call for a complete exit due to ongoing security concerns and lack of transparency from the development team.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending as the community anticipates a decision on the FDA's PDUFA date for the use of Auvelity in treating Alzheimer's disease agitation. Investors are keenly focused on upcoming pipeline developments and potential sales acceleration, while ongoing discussions highlight the strategic value of the company's CNS portfolio and its path toward profitability.

Albemarle Corp. engages in the development, manufacture, and marketing of chemicals for consumer electronics, petroleum refining, utilities, packaging, construction, transportation, pharmaceuticals, crop production, food-safety, and custom chemistry services. It operates through the following segments: Energy Storage, Specialties, and Ketjen. The Energy Storage segment develops and manufactures a broad range of basic lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride. The Specialties segment focuses on optimizing a portfolio of bromine and specialized lithium solutions. The Ketjen segment consists of clean fuels technologies, fluidized catalytic cracking catalysts and additives, and performance catalyst solutions, which is primarily composed of organometallics and curatives. The company was founded in 1993 and is headquartered in Charlotte, NC.

Albemarle Corp.

Albemarle Corp

Albemarle is trending as investors aggressively build positions in anticipation of a potential lithium market supercycle, driven by increasing demand for energy storage and expectations of an earnings beat. The stock has seen massive institutional accumulation and significant price appreciation, with community sentiment shifting from caution to bullish momentum as analysts upgrade targets and lithium futures show sustained strength.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending as investors rotate into the stock as a perceived safe haven, leading the company to challenge Nvidia for the title of the world's most valuable firm despite ongoing debates about its AI strategy and valuation. The community is actively discussing the stock's relentless climb, with many debating whether it represents a genuine rotation into stability or an overextended rally driven by institutional flows and algo-driven price action.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk Corp ($SNDK) is experiencing extreme volatility as traders debate whether recent aggressive selling represents a fundamental reset or a temporary washout driven by forced liquidations and options expiration positioning. While some investors see an elite asymmetric opportunity tied to long-term AI memory demand, others remain wary of the stock's massive retrace from historic highs and ongoing sector-wide price instability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that results from a Phase 1 study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in advanced clear cell renal...

A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs

A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs PR Newswire SAN FRANCISCO, July 6, 2026 Issued on...

The Biology Came First.

MindWalk Holdings Corp. (NASDAQ: HYFT) today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at...

Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates

Xencor (XNCR) delivered earnings and revenue surprises of -164.58% and -75.38%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Xencor Reports First Quarter 2026 Financial Results

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the...

Xencor Highlights XmAb942 Phase 1 Data, Previews TL1A/IL-23 Bispecific XmAb412 at DDW 2026

Xencor (NASDAQ:XNCR) used a webcast during Digestive Disease Week 2026 to highlight Phase I results for its TL1A-targeting monoclonal antibody XmAb942 and to outline preclinical data supporting...

Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported final results from the...

Corcept Therapeutics (CORT) Reports Q1 Loss, Misses Revenue Estimates

Corcept (CORT) delivered earnings and revenue surprises of -1.11% and -4.37%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Xencor (XNCR) Projected to Post Earnings on Wednesday

Xencor (NASDAQ:XNCR) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-6-xencor-inc-stock...

Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Shares of Xencor, Inc. (NASDAQ:XNCR - Get Free Report) have received a consensus rating of "Moderate Buy" from the nine analysts that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assig...

Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Pasadena, CA.

Xencor Inc

Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is pacing for a losing week as a semiconductor ($SMH) sell-off has dragged the market lower amid growing doubts about AI spending. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.81	--	--	N/A
Q1 '26	-$0.67	-$1.71	-155.58%	MISSED
Q4 '25	-$0.60	-$0.09	85.03%	BEAT
Q3 '25	-$0.69	-$0.08	88.38%	BEAT
Q2 '25	-$0.72	-$0.41	43.04%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

XNCRXencor Inc

Upcoming Earnings: Q2 '26

Historical Earnings

Latest XNCR News